{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:53:07Z","timestamp":1791078787793,"version":"4.1.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2013,7,6]],"date-time":"2013-07-06T00:00:00Z","timestamp":1373068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>The spectrum of therapeutic options and the amount of clinical trials for male osteoporosis (mOP) is lower than those for postmenopausal osteoporosis. Therefore, we examined the effects of 24 months of ibandronate (IBN) treatment (3\u2009mg\/3\u2009mL intravenously every 3 months) on bone material quality in 19 subjects with mOP within an open-label, single-center, prospective phase III study (Eudract number 2006-006692-20). Patients (median age [25th, 75th percentiles] 53.0 [44.5; 57.0] years) were included if they had low bone mineral density (BMD) and\/or at least one low trauma fracture and no secondary cause of osteoporosis. The primary endpoint was to evaluate IBN effects on cancellous (Cn.) and cortical (Ct.) bone mineralization density distribution (BMDD) based on quantitative backscattered electron imaging (qBEI) of paired transiliacal bone biopsies (baseline, 24 months). Secondary endpoints included changes in areal bone mineral density (BMD by dual-energy X-ray absorptiometry [DXA]) and serum markers of bone turnover including type I collagen peptides CrossLaps (CTX), procollagen type 1 amino-terminal propeptide (P1NP), and osteocalcin (OC). At baseline, cancellous bone matrix mineralization from mOP was lower than published reference data (mean degree of mineralization Cn.CaMean \u22121.8%, p\u2009&amp;lt;\u20090.01). IBN treatment increased calcium concentrations versus baseline (Cn.CaMean +2.4%, Ct.CaMean, +3.0% both p\u2009&amp;lt;\u20090.01), and reduced heterogeneity of mineralization (Cn.CaWidth \u221214%, p\u2009=\u20090.044; Ct.CaWidth, \u221216%, p\u2009=\u20090.001), leading to cancellous BMDD within normal range. IBN treatment was associated with a decrease in porosity of mineralized cortical tissue (\u221225%, p\u2009=\u20090.01); increases in BMD at the lumbar spine, the femoral neck, and the total hip (+3.3%, +1.9%, and +5.6%, respectively, p \u2264 0.01); and reductions in CTX (\u221237.5%), P1NP (\u221244.4%), and OC (\u221236.3%, all p\u2009&amp;lt;\u20090.01). Our BMDD findings are in line with the reduction of bone turnover markers and the increase in BMD by IBN in our patients and suggest that the latter mainly reflects the increase in matrix mineralization and the reduction of cortical porosity in this cohort with mOP. \u00a9 2014 American Society for Bone and Mineral Research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.2035","type":"journal-article","created":{"date-parts":[[2013,7,6]],"date-time":"2013-07-06T08:34:41Z","timestamp":1373099681000},"page":"440-449","source":"Crossref","is-referenced-by-count":25,"title":["Intravenous Treatment With Ibandronate Normalizes Bone Matrix Mineralization and Reduces Cortical Porosity After Two Years in Male Osteoporosis: A Paired Biopsy Study"],"prefix":"10.1093","volume":"29","author":[{"given":"Barbara M","family":"Misof","sequence":"first","affiliation":[{"name":"Ludwig Boltzmann Institute of OsteologyHanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch HospitalViennaAustria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina M","family":"Patsch","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and ImmunologyMedical University of ViennaViennaAustria"},{"name":"Department of RadiologyMedical University of ViennaViennaAustria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Roschger","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of OsteologyHanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch HospitalViennaAustria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Muschitz","sequence":"additional","affiliation":[{"name":"Medical Department II with Osteology\/Rheumatology and GastroenterologyKH Barmherzige Schwestern (St. Vincent Hospital) Vienna, Academic Teaching Hospital of the Medical University Vienna, VINFORCE study groupViennaAustria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Gamsjaeger","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of OsteologyHanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch HospitalViennaAustria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios P","family":"Paschalis","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of OsteologyHanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch HospitalViennaAustria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Prokop","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of OsteologyHanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch HospitalViennaAustria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Klaushofer","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of OsteologyHanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch HospitalViennaAustria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pietschmann","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and ImmunologyMedical University of ViennaViennaAustria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Resch","sequence":"additional","affiliation":[{"name":"Medical Department II with Osteology\/Rheumatology and GastroenterologyKH Barmherzige Schwestern (St. Vincent Hospital) Vienna, Academic Teaching Hospital of the Medical University Vienna, VINFORCE study groupViennaAustria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,7,6]]},"reference":[{"issue":"1","key":"2024020318572375300_jbmr2035-bib-0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1210\/jc.2009-1740","article-title":"Update in male osteoporosis","volume":"95","author":"Khosla","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318572375300_jbmr2035-bib-0002","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(02)08706-8","article-title":"Pathogenesis of bone fragility in women and men","volume":"359","author":"Seeman","year":"2002","journal-title":"Lancet."},{"issue":"4","key":"2024020318572375300_jbmr2035-bib-0003","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00223-001-1048-4","article-title":"Secondary causes of osteoporosis in men","volume":"69","author":"Compston","year":"2001","journal-title":"Calcif Tissue Int."},{"issue":"1","key":"2024020318572375300_jbmr2035-bib-0004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0149-2918(04)90002-1","article-title":"Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment","volume":"26","author":"Olszynski","year":"2004","journal-title":"Clin Ther."},{"key":"2024020318572375300_jbmr2035-bib-0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide (human parathyroid hormone (1-34)) therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res."},{"issue":"10","key":"2024020318572375300_jbmr2035-bib-0006","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/jbmr.119","article-title":"Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study","volume":"25","author":"Orwoll","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"11","key":"2024020318572375300_jbmr2035-bib-0007","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1210\/jcem.86.11.7988","article-title":"Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study","volume":"86","author":"Ringe","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2024020318572375300_jbmr2035-bib-0008","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/PL00004182","article-title":"Effects of alendronate on bone density in men with primary and secondary osteoporosis","volume":"11","author":"Ho","year":"2001","journal-title":"Osteoporos Int."},{"issue":"1","key":"2024020318572375300_jbmr2035-bib-0009","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bone.2011.10.024","article-title":"Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate","volume":"50","author":"Sambrook","year":"2012","journal-title":"Bone."},{"key":"2024020318572375300_jbmr2035-bib-0010","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/BF03347354","article-title":"Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years","volume":"26","author":"Lamy","year":"2003","journal-title":"J Endocrinol Invest."},{"issue":"5","key":"2024020318572375300_jbmr2035-bib-0011","first-page":"267","article-title":"Efficacy of strontium ranelate on bone mineral density in men with osteoporosis","volume":"60","author":"Ringe","year":"2010","journal-title":"Arzneimittelforschung."},{"key":"2024020318572375300_jbmr2035-bib-0012","first-page":"5252","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"86","author":"Orwoll","year":"2000","journal-title":"N Engl J Med."},{"issue":"4","key":"2024020318572375300_jbmr2035-bib-0013","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00223-001-1060-8","article-title":"Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy","volume":"69","author":"Reid","year":"2001","journal-title":"Calcif Tissue Int."},{"issue":"15","key":"2024020318572375300_jbmr2035-bib-0014","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/archinte.165.15.1743","article-title":"Risedronate sodium therapy for prevention of hip fractures in men 65 years or older after stroke","volume":"165","author":"Sato","year":"2005","journal-title":"Arch Intern Med."},{"issue":"18","key":"2024020318572375300_jbmr2035-bib-0015","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N Engl J Med."},{"key":"2024020318572375300_jbmr2035-bib-0016","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev.matsci.28.1.271","article-title":"The material bone: structure\u2013function relations","volume":"28","author":"Weiner","year":"1998","journal-title":"Annu Rev Mater Sci."},{"key":"2024020318572375300_jbmr2035-bib-0017","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1039\/B402005G","article-title":"Structure and mechanical quality of the collagen-mineral nano-composite in bone","volume":"14","author":"Fratzl","year":"2004","journal-title":"J Material Chem."},{"key":"2024020318572375300_jbmr2035-bib-0018","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality\u2014the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N Engl J Med."},{"key":"2024020318572375300_jbmr2035-bib-0019","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S8756-3282(02)00973-0","article-title":"Constant mineralization density distribution in cancellous human bone","volume":"32","author":"Roschger","year":"2003","journal-title":"Bone."},{"key":"2024020318572375300_jbmr2035-bib-0020","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bone.2007.10.021","article-title":"Bone mineralization density distribution in health and disease","volume":"42","author":"Roschger","year":"2008","journal-title":"Bone."},{"key":"2024020318572375300_jbmr2035-bib-0021","first-page":"1212","article-title":"Assessment of vertebral fractures in osteoporosis research","volume":"24","author":"Genant","year":"1997","journal-title":"J Rheumatol."},{"key":"2024020318572375300_jbmr2035-bib-0022","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jbmr.5650060106","article-title":"A comparison of morphometric definitions of vertebral fracture","volume":"6","author":"Smith-Bindman","year":"1991","journal-title":"J Bone Miner Res."},{"key":"2024020318572375300_jbmr2035-bib-0023","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.5650110716","article-title":"Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group","volume":"11","author":"Genant","year":"1996","journal-title":"J Bone Miner Res."},{"key":"2024020318572375300_jbmr2035-bib-0024","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/jbmr.344","article-title":"Trabecular bone microstructure and local gene expression in iliac crest biopsies of men with idiopathic osteoporosis","volume":"26","author":"Patsch","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020318572375300_jbmr2035-bib-0025","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res."},{"issue":"6","key":"2024020318572375300_jbmr2035-bib-0026","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/jcp.47.6.529","article-title":"Age related histomorphometric changes in bone in normal British men and women","volume":"47","author":"Rehman","year":"1994","journal-title":"J Clin Pathol."},{"key":"2024020318572375300_jbmr2035-bib-0027","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S8756-3282(98)00112-4","article-title":"Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies","volume":"23","author":"Roschger","year":"1998","journal-title":"Bone."},{"key":"2024020318572375300_jbmr2035-bib-0028","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00223-007-9039-8","article-title":"Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume","volume":"81","author":"Fratzl","year":"2007","journal-title":"Calcif Tissue Int."},{"key":"2024020318572375300_jbmr2035-bib-0029","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1047-8477(02)00635-4","article-title":"Characteristics of mineral particles in the human bone\/cartilage interface","volume":"141","author":"Zizak","year":"2003","journal-title":"J Struct Biol."},{"key":"2024020318572375300_jbmr2035-bib-0030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ar.1091490302","article-title":"The density of organic and volatile and non-volatile inorganic components of bone","volume":"149","author":"Gong","year":"1964","journal-title":"Anat Rec."},{"issue":"3","key":"2024020318572375300_jbmr2035-bib-0031","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.bone.2008.11.004","article-title":"Vertebral fractures are associated with increased cortical porosity in iliac crest bone biopsy of men with idiopathic osteoporosis","volume":"44","author":"Ostertag","year":"2009","journal-title":"Bone."},{"key":"2024020318572375300_jbmr2035-bib-0032","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.bone.2004.12.008","article-title":"Bone histomorphometry in 22 male patients with normocalciuric idiopathic osteoporosis","volume":"36","author":"Ciria-Recasens","year":"2005","journal-title":"Bone."},{"key":"2024020318572375300_jbmr2035-bib-0033","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s00223-005-0158-9","article-title":"Osteoblast dysfunction in male idiopathic osteoporosis","volume":"78","author":"Pernow","year":"2006","journal-title":"Calcif Tissue Int."},{"issue":"6","key":"2024020318572375300_jbmr2035-bib-0034","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s00223-009-9239-5","article-title":"Bone histomorphometry in male idiopathic osteoporosis","volume":"84","author":"Pernow","year":"2009","journal-title":"Calcif Tissue Int."},{"key":"2024020318572375300_jbmr2035-bib-0035","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00223-010-9336-5","article-title":"Reduced proliferation and osteocalcin expression in osteoblasts of male idiopathic osteoporosis","volume":"86","author":"Ruiz-Gaspa","year":"2010","journal-title":"Calcif Tissue Int."},{"key":"2024020318572375300_jbmr2035-bib-0036","first-page":"2792","article-title":"Idiopathic osteoporosis: is the osteoblast to blame","volume":"82","author":"Khosla","year":"1997","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318572375300_jbmr2035-bib-0037","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone."},{"issue":"2","key":"2024020318572375300_jbmr2035-bib-0038","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S8756-3282(01)00485-9","article-title":"Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women","volume":"29","author":"Roschger","year":"2001","journal-title":"Bone."},{"key":"2024020318572375300_jbmr2035-bib-0039","first-page":"538","article-title":"Effects of bisphosphonates on matrix mineralization","volume":"2","author":"Boivin","year":"2002","journal-title":"J Musculoskelet Neuronal Interact."},{"key":"2024020318572375300_jbmr2035-bib-0040","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1359\/jbmr.060401","article-title":"Effects of 3- and 5-year treatment with Risedronate on the bone mineral density distribution of cancellous bone in human iliac crest biopsies","volume":"21","author":"Zoehrer","year":"2006","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2024020318572375300_jbmr2035-bib-0041","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00223-011-9466-4","article-title":"Fragility fractures in men with idiopathic osteoporosis are associated with undermineralization of the bone matrix without evidence of increased bone turnover","volume":"88","author":"Fratzl-Zelman","year":"2011","journal-title":"Calcif Tissue Int."},{"issue":"12","key":"2024020318572375300_jbmr2035-bib-0042","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1002\/jbmr.1699","article-title":"Bone material properties in premenopausal women with idiopathic osteoporosis","volume":"27","author":"Misof","year":"2012","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2024020318572375300_jbmr2035-bib-0043","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bone.2008.05.024","article-title":"The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patients","volume":"43","author":"Boivin","year":"2008","journal-title":"Bone."},{"key":"2024020318572375300_jbmr2035-bib-0044","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.bone.2007.01.012","article-title":"The bone mineralization density distribution as a fingerprint of the mineralization process","volume":"40","author":"Ruffoni","year":"2007","journal-title":"Bone."},{"key":"2024020318572375300_jbmr2035-bib-0045","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1359\/JBMR.040710","article-title":"Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients","volume":"19","author":"Recker","year":"2004","journal-title":"J Bone Miner Res."},{"key":"2024020318572375300_jbmr2035-bib-0046","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bone.2006.01.161","article-title":"Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography","volume":"39","author":"Borah","year":"2006","journal-title":"Bone."},{"issue":"3","key":"2024020318572375300_jbmr2035-bib-0047","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/jbmr.1780","article-title":"Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort","volume":"28","author":"Misof","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"18","key":"2024020318572375300_jbmr2035-bib-0048","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"key":"2024020318572375300_jbmr2035-bib-0049","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00223-008-9161-2","article-title":"Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation","volume":"83","author":"Misof","year":"2008","journal-title":"Calcif Tissue Int."},{"issue":"1","key":"2024020318572375300_jbmr2035-bib-0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1359\/jbmr.090711","article-title":"Risedronate reduces intracortical porosity in women with osteoporosis","volume":"25","author":"Borah","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2024020318572375300_jbmr2035-bib-0051","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/8756-3282(88)90012-9","article-title":"Trabecular architecture in iliac crest bone biopsies: infra-individual variability in structural parameters and changes with age","volume":"9","author":"Parisien","year":"1988","journal-title":"Bone."},{"issue":"4","key":"2024020318572375300_jbmr2035-bib-0052","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/154405910708600413","article-title":"Cortical vascular canals in human mandible and other bones","volume":"86","author":"Kingsmill","year":"2007","journal-title":"J Dent Res."},{"issue":"11","key":"2024020318572375300_jbmr2035-bib-0053","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/j.1742-1241.2006.01148.x","article-title":"Hip and non-spine fracture risk reductions differ among antiresorptive agents: evidence from randomised controlled trials","volume":"60","author":"Liberman","year":"2006","journal-title":"Int J Clin Pract."},{"issue":"1","key":"2024020318572375300_jbmr2035-bib-0054","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00198-011-1732-9","article-title":"Effect of monthly ibandronate on hip structural geometry in men with low bone density","volume":"23","author":"Genant","year":"2012","journal-title":"Osteoporos Int."},{"issue":"2","key":"2024020318572375300_jbmr2035-bib-0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00223-013-9734-6","article-title":"Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg\/month intravenous ibandronate versus 2.5 mg\/day oral risedronate in patients with primary osteoporosis","volume":"93","author":"Nakamura","year":"2013","journal-title":"Calcif Tissue Int."},{"issue":"9727","key":"2024020318572375300_jbmr2035-bib-0056","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(10)60320-0","article-title":"Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study","volume":"375","author":"Zebaze","year":"2010","journal-title":"Lancet."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2035","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/29\/2\/440\/56566222\/jbmr2035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/29\/2\/440\/56566222\/jbmr2035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:49:59Z","timestamp":1710341399000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/29\/2\/440-449\/7599004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,6]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,7,6]]},"published-print":{"date-parts":[[2014,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.2035","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,2,1]]},"published":{"date-parts":[[2013,7,6]]}}}